Adding the thrombopoietin receptor agonist eltrombopag (Revolade) to standard immunosuppressive treatment increases response rates in patients with Severe Aplastic Anaemia (SAA), preliminary results from the phase III RACE trial show. The trial (see abstract here), which was awarded the prestigious van Bekkum award at this year’s European Society for Blood and Marrow Transplantation virtual 46th ...
Award-winning study ‘practice changing’ for severe aplastic anaemia
By Nicola Garrett
3 Sep 2020